Analysis of Risk Factors for Kidney Retransplant Outcomes Associated with Common Induction Regimens: A Study of over Twelve-Thousand Cases in the United States
Table 1
Demographic and Clinical characteristics of adults receiving repeat kidney transplants in the United States from 2003 through 2013.
Variables
Antithymocyte globulin
Alemtuzumab
Basiliximab
p Value
Donor type:
<.001
Expanded criteria deceased
475 (5.21)
116 (6.88)
106 (4.96)
Standard criteria deceased
6008 (65.88)
996 (59.04)
1103 (51.61)
Living
2637 (28.91)
575 (34.08)
928 (43.43)
Donor race:
<.001
Black
1145 (12.55)
206 (12.21)
191 (8.94)
Others
7975 (87.45)
1481 (87.79)
1946 (91.06)
Recipient age, years:
Mean (SD)
44.36 (12.59)
44.69 (13.07)
46.15 (13.43)
<.001
Range
18–78
18–79
18–88
—
Recipient race:
<.001
Black
2077 (22.77)
389 (23.06)
314 (14.69)
Others
7043 (77.23)
1298 (76.94)
1823 (85.31)
Primary kidney disease:
Glomerulonephritis
3417 (37.47)
632 (37.46)
776 (36.31)
0.60
Pretransplant dialysis:
<.001
1 day–1 year
1392 (15.26)
291 (17.25)
462 (21.62)
>1 year
6515 (71.44)
1154 (68.41)
1217 (56.95)
No dialysis
1213 (13.30)
242 (14.34)
458 (21.43)
Pretransplant PRA:
<.001
PRA 0–20%
2408 (26.40)
446 (26.44)
981 (45.91)
PRA > 20%
6712 (73.60)
1241 (73.56)
1156 (54.09)
HLA mismatch
<.001
0–3
4215 (46.31)
801 (47.57)
1116 (52.30)
More than 3
4886 (53.69)
883 (52.43)
1018 (47.70)
Transplant year:
<.001
2003–2008
4344 (47.63)
656 (38.89)
1299 (60.79)
2009–2013
4776 (52.37)
1031 (61.11)
838 (39.21)
Steroids included in maintenance Immunosuppression regimen:
